Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Dyslipidemia

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 15 articles: HTML format

Single Articles

September 2022
1. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
   Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
   N Engl J Med. 2022;387:1075-1088.
   PubMed     Abstract available
   
   
   July 2021
2. BJORNSTAD P, Drews KL, Caprio S, Gubitosi-Klug R, et al
   Long-Term Complications in Youth-Onset Type 2 Diabetes.
   N Engl J Med. 2021;385:416-426.
   PubMed     Abstract available
   
   
   March 2021
3. GIBBONS GH, Seidman CE, Topol EJ
   Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress.
   N Engl J Med. 2021;384:785-788.
   PubMed    
   
   
   February 2021
4. RAAL FJ, Gaudet D, Gusarova V
   Evinacumab for Homozygous Familial Hypercholesterolemia. Reply.
   N Engl J Med. 2021;384:e17.
   PubMed    
   
   
   
5. XU HG
   Evinacumab for Homozygous Familial Hypercholesterolemia.
   N Engl J Med. 2021;384:e17.
   PubMed    
   
   
   
6. LUO F, Das A, Fang Z
   Evinacumab for Homozygous Familial Hypercholesterolemia.
   N Engl J Med. 2021;384:e17.
   PubMed    
   
   
   
7. AGIRBASLI M
   Evinacumab for Homozygous Familial Hypercholesterolemia.
   N Engl J Med. 2021;384:e17.
   PubMed    
   
   
   January 2021
8. GAUDET D, Ruzza A, Santos RD
   Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Reply.
   N Engl J Med. 2021;384:84-85.
   PubMed    
   
   
   
9. SINGH A, Mittal S, Kazimuddin M
   Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
   N Engl J Med. 2021;384:84.
   PubMed    
   
   
   December 2020
10. MARTIN SS
    Factoring in ANGPTL3 When LDL Is Refractory.
    N Engl J Med. 2020;383:2385-2386.
    PubMed    
    
    
    November 2020
11. SHAW AT, Bauer TM, de Marinis F, Felip E, et al
    First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    N Engl J Med. 2020;383:2018-2029.
    PubMed     Abstract available
    
    
    
12. ROSENSON RS, Burgess LJ, Ebenbichler CF, Baum SJ, et al
    Evinacumab in Patients with Refractory Hypercholesterolemia.
    N Engl J Med. 2020 Nov 15. doi: 10.1056/NEJMoa2031049.
    PubMed     Abstract available
    
    
    October 2020
13. DE FERRANTI SD
    Evolocumab in Children with Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:1385-1386.
    PubMed    
    
    
    August 2020
14. SANTOS RD, Ruzza A, Hovingh GK, Wiegman A, et al
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019910.
    PubMed     Abstract available
    
    
    March 2020
15. RAAL FJ, Kallend D, Ray KK, Turner T, et al
    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa1913805.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: